Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02578017 · ClinicalTrials.gov registry record · NA
ElectroNic Hydroxyurea AdhereNCE: A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease
A NA study, sponsored by Nationwide Children's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 71
- Enrollment target
NCT02578017 is a NA study that has completed, run by Nationwide Children's Hospital. The registered enrollment target is 71 participants.
The verdict
NCT02578017, a NA study, has completed, sponsored by Nationwide Children's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 71 participants
- Enrollment target
Study Summary
HU is an FDA approved medication for the treatment of SCD. Many studies have shown that HU can reduce SCD related symptoms, but only 50% of patients take it as often as they should. This limits how much HU can help reduce SCD symptoms. Researchers are interested to see if electronic directly observed therapy (Mobile DOT), a program that uses cell phone reminder messages, videos, feedback messages, and incentives will help patients with SCD take HU as prescribed.
Interventions
- BEHAVIORAL Mobile DOT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2014-07 |
| Est. Completion | 2019-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02578017
The ClinicalTrials.gov registry entry for NCT02578017 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mobile DOT is the first listed.
NCT02578017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02578017 about?
NCT02578017 is a clinical study titled "ElectroNic Hydroxyurea AdhereNCE: A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease". HU is an FDA approved medication for the treatment of SCD. Many studies have shown that HU can reduce SCD related symptoms, but only 50% of patients take it as often as they should. This limits how much HU can help reduce SCD symptoms. Researchers are interested to see if electronic directly observ...
What is the current status of trial NCT02578017?
This trial is currently completed. It is a NA study. The enrollment target is 71 participants. The study started on 2014-07. Estimated completion is 2019-06.
What interventions are being tested in trial NCT02578017?
The interventions under investigation include: Mobile DOT (BEHAVIORAL).
Who is sponsoring clinical trial NCT02578017?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.